Across TCGA pan-cancer cohorts, ACTG1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTG1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ACTG1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTG1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

ACC, BLCA, and HNSC are the cancer types where ACTG1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.049	0.675	<.001	39	view →
BLCA	OS	Median	III,IV	1.000	0.342	.008	14	view →
HNSC	DFS	Median	IV	0.148	0.669	.020	6	view →
SKCM	DFS	Median	All	0.972	0.730	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ACTG1 tumor-vs-normal RNA expression · all ACTG1 data types